1. United States Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Innoveren Scientific Inc.

Innoveren Scientific Inc.

OOTC:IVRN
0.00
USD
+0.00
(-25.00%)
-4.36EPS
240,545.39Market Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
TTM
Revenue per Share
- -
- -
3.02
- -
10.83
34.88
86.61
19.29
11.06
1.54
- -
Basic EPS, GAAP
-73.41
-371.92
-596.1
-1,224.72
-337.29
-211.72
-341.14
-60.82
-32.93
-35.06
-5.11
Free Cash Flow per Basic Share
-62.98
-352.48
-547.29
-416.05
-292.92
-99.8
-127.76
-65.12
-33.06
-6.51
-1.44
Dividend per Share
- -
- -
- -
- -
- -
- -
0.15
- -
- -
- -
- -
Book Value per Share
280.9
709.29
907.2
-30.16
33.71
-80.79
-91.12
-9.56
-31.45
-15.84
-15.91
Tangible Book Value per Share
280.9
709.29
322.87
-30.16
33.71
-80.79
-91.12
-9.56
-31.45
-15.84
-15.91
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
1
8
2
2
- -
- -
Operating Margin (%)
- -
- -
-16,757.64
- -
-2,923.13
-573.67
-180.31
-329.77
-322.23
-674.36
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
1
- -
- -
- -
- -
Net Income, GAAP
-1
-3
-7
-16
-6
-5
-30
-6
-5
-10
-3
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-19,739.98
- -
-3,113.9
-599.92
-357.11
-300.34
-297.81
-2,271.33
- -
Working Capital
3
6
1
-1
1
-2
-3
-1
-5
-7
-9
LT Debt
- -
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
3
7
10
- -
1
-2
-3
-1
-5
-9
-11
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-64.68
-78.93
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

USD

•

in mil. unless spec.
Mar'23
Jun'23
Sep'23
ST Debt
6
4
4
LT Borrowings
2
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1
1
1
Market Capitalization
1
1
- -

Working Capital

USD

•

in mil. unless spec.
Mar'23
Jun'23
Sep'23
Total Current Assets
- -
- -
1
Cash, Cash Equivalents & STI
- -
- -
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
10
9
10
Payables & Accruals
3
3
4
ST Debt
6
4
4
Deferred Revenue
- -
- -
1

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
13.37%
100.71%
Free Cash Flow
- -
46.54%
-60.28%
Net Income, GAAP
- -
98.77%
114.61%
Sales/Revenue/Turnover
- -
208.72%
-71.86%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
2
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-10.97
-14.9
-4.12
-4.55
-32.93
2022
-23.01
-11.97
-8.04
-2.41
-35.06
2023
-3.38
1.3
-0.73
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Michael W. Yurkowsky
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Cincinnati United States
IPO Date
Dec 19, 2014
Website
ir.hcyte.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Innoveren Scientific Inc. is a hybrid biopharmaceutical and medical technology company focused on the acquisition, clinical development, and commercialization of early-stage healthcare technologies across regenerative medicine, oncology therapeutics, and specialized medical devices. The company operates through distinct biomedical development divisions and maintains a portfolio of proprietary therapeutic and surgical solutions; its core product lines and development assets comprise SkinDisc, an autologous regenerative biologic and cellular matrix platform engineered for advanced wound management, tissue repair, and limb salvage in chronic wound care; SkinDisc Lite, a point-of-care preparation system utilizing autologous platelet-rich plasma and protein concentrates to facilitate tissue regeneration; the DenerveX System, a patented, minimally invasive electrosurgical medical device combining rotational capsular tissue shaving with controlled thermal radiofrequency ablation for the long-term denervation and treatment of chronic facet joint syndrome and low back pain; and preclinical fusion protein immunotherapies developed to treat refractory solid tumor malignancies, specifically ovarian cancer, pancreatic cancer, and malignant mesothelioma. Innoveren Scientific Inc. primarily targets healthcare institutions, ambulatory surgical centers, orthopedic and pain specialists, oncologists, and advanced wound care providers across the United States. In recent developments, the company has executed a major strategic transformation, shifting its operational focus from historical clinical cellular therapy services toward biopharmaceutical and medical device incubation; this restructuring included rebranding the corporate entity from H-CYTE, Inc. to Innoveren Scientific Inc. in July 2023, following its earlier origin as Medovex Corp. Furthermore, the company expanded its therapeutic pipeline through the strategic acquisitions of Jantibody LLC, adding targeted immuno-oncology assets, and Scion Solutions, LLC, securing the SkinDisc regenerative biologic portfolio, while advancing regulatory milestones including U.S. Food and Drug Administration 510(k) clearance filings for its SkinDisc product line. Innoveren Scientific Inc. was founded in 2013 and is headquartered in Cincinnati, Ohio.